<unk>  is a moderate to strong inducer of multiple cytochrome P450 enzymes including CYP3A4, CYP2C9, and CYP2C19 and hence has a high potential for clinically relevant drug interactions. Circulating concentrations of<unk>  may be altered by inhibitors and inducers of CYP2C8 and CYP3A4, and should be avoided if possible. In a clinical study of<unk>  for -positive breast cancer in women,<unk>  was found to decrease serum concentrations of the aromatase inhibitors anastrozole and exemestane by 90% and 50%, respectively, which could reduce their effectiveness.
Enzalutamide
Bicalutamide
Flutamide
Apalutamide
Nilutamide
Topilutamide
Darolutamide
Tamoxifen